ID   FLT3_HUMAN              Reviewed;         993 AA.
AC   P36888; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0; Q13414;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 2.
DT   10-MAY-2017, entry version 174.
DE   RecName: Full=Receptor-type tyrosine-protein kinase FLT3;
DE            EC=2.7.10.1;
DE   AltName: Full=FL cytokine receptor;
DE   AltName: Full=Fetal liver kinase-2;
DE            Short=FLK-2;
DE   AltName: Full=Fms-like tyrosine kinase 3;
DE            Short=FLT-3;
DE   AltName: Full=Stem cell tyrosine kinase 1;
DE            Short=STK-1;
DE   AltName: CD_antigen=CD135;
DE   Flags: Precursor;
GN   Name=FLT3; Synonyms=CD135, FLK2, STK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=7507245; DOI=10.1073/pnas.91.2.459;
RA   Small D., Levenstein M., Kim E., Carow C., Amin S., Rockwell P.,
RA   Witte L., Burrow C., Ratajczak M.Z., Gewirtz A.M., Civin C.I.;
RT   "STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in
RT   CD34+ human bone marrow cells and is involved in the proliferation of
RT   early progenitor/stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:459-463(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT MET-227.
RC   TISSUE=Lymphocyte;
RX   PubMed=8394751;
RA   Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C.,
RA   Toiron Y., Birg F., Birnbaum D.;
RT   "Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic
RT   cells.";
RL   Blood 82:1110-1119(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-227.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-227.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 783-942 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2004790; DOI=10.1016/0888-7543(91)90270-O;
RA   Rosnet O., Mattei M.-G., Marchetto S., Birnbaum D.;
RT   "Isolation and chromosomal localization of a novel FMS-like tyrosine
RT   kinase gene.";
RL   Genomics 9:380-385(1991).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=8637232;
RA   Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C.,
RA   Sainty D., Arnoulet C., Chabannon C., Kanz L., Hannum C., Birnbaum D.;
RT   "Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface
RT   of normal and malignant hematopoietic cells.";
RL   Leukemia 10:238-248(1996).
RN   [8]
RP   INVOLVEMENT IN AML.
RX   PubMed=8946930;
RA   Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K.,
RA   Sonoda Y., Fujimoto T., Misawa S.;
RT   "Internal tandem duplication of the flt3 gene found in acute myeloid
RT   leukemia.";
RL   Leukemia 10:1911-1918(1996).
RN   [9]
RP   INVOLVEMENT IN AML, SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF
RP   TYR-589 AND TYR-591.
RX   PubMed=9737679; DOI=10.1038/sj.leu.2401130;
RA   Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H.,
RA   Naoe T.;
RT   "Internal tandem duplication of the FLT3 gene is a novel modality of
RT   elongation mutation which causes constitutive activation of the
RT   product.";
RL   Leukemia 12:1333-1337(1998).
RN   [10]
RP   FUNCTION IN PROMOTING PHOSPHORYLATION OF SHC1; PTPN6/SHP;
RP   PTPN11/SHP-2; MAPK1/ERK2; MAPK3/ERK1, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH GRB2.
RX   PubMed=10080542;
RA   Zhang S., Mantel C., Broxmeyer H.E.;
RT   "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and
RT   their association with Grb2 and Shc in Baf3/Flt3 cells.";
RL   J. Leukoc. Biol. 65:372-380(1999).
RN   [11]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT5A AND
RP   STAT5B, PHOSPHORYLATION, FUNCTION IN ACTIVATION OF THE RAS PATHWAY,
RP   AND INVOLVEMENT IN AML.
RX   PubMed=11090077;
RA   Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C.,
RA   Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T.,
RA   Kienast J., Kanakura Y., Berdel W.E., Serve H.;
RT   "Flt3 mutations from patients with acute myeloid leukemia induce
RT   transformation of 32D cells mediated by the Ras and STAT5 pathways.";
RL   Blood 96:3907-3914(2000).
RN   [12]
RP   FUNCTION IN ACTIVATION OF AKT1, AND INVOLVEMENT IN AML.
RX   PubMed=16266983; DOI=10.1158/0008-5472.CAN-05-0422;
RA   Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B.,
RA   Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M.,
RA   Berdel W.E., Serve H.;
RT   "Constitutive activation of Akt by Flt3 internal tandem duplications
RT   is necessary for increased survival, proliferation, and myeloid
RT   transformation.";
RL   Cancer Res. 65:9643-9650(2005).
RN   [13]
RP   SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-591,
RP   DEPHOSPHORYLATION BY PTPN1; PTPN6/SHP-1 AND PTPN12, PROTEASOMAL
RP   DEGRADATION, GLYCOSYLATION, AND MUTAGENESIS OF LYS-644.
RX   PubMed=15831474; DOI=10.1128/MCB.25.9.3690-3703.2005;
RA   Schmidt-Arras D.E., Bohmer A., Markova B., Choudhary C., Serve H.,
RA   Bohmer F.D.;
RT   "Tyrosine phosphorylation regulates maturation of receptor tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 25:3690-3703(2005).
RN   [14]
RP   FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION AT
RP   TYR-591; TYR-726; TYR-842; TYR-955 AND TYR-969, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF TYR-589 AND TYR-591.
RX   PubMed=16627759; DOI=10.1182/blood-2005-11-011429;
RA   Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P.,
RA   Gilliland D.G.;
RT   "Roles of tyrosine 589 and 591 in STAT5 activation and transformation
RT   mediated by FLT3-ITD.";
RL   Blood 108:1339-1345(2006).
RN   [15]
RP   INTERACTION WITH PTPN11/SHP2; LYN; FGR; HCK AND SRC,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-589 AND TYR-599, AND
RP   PHOSPHORYLATION AT TYR-572; SER-574; TYR-589; TYR-591 AND TYR-599.
RX   PubMed=16684964; DOI=10.1182/blood-2005-07-008896;
RA   Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S.,
RA   Ronnstrand L.;
RT   "Identification of Y589 and Y599 in the juxtamembrane domain of Flt3
RT   as ligand-induced autophosphorylation sites involved in binding of Src
RT   family kinases and the protein tyrosine phosphatase SHP2.";
RL   Blood 108:1542-1550(2006).
RN   [16]
RP   REGION INVOLVED IN REGULATION OF KINASE ACTIVITY, AUTOREGULATORY
RP   DOMAIN, AND INVOLVEMENT IN AML.
RX   PubMed=18305215; DOI=10.1182/blood-2008-01-117770;
RA   Meshinchi S., Stirewalt D.L., Alonzo T.A., Boggon T.J., Gerbing R.B.,
RA   Rocnik J.L., Lange B.J., Gilliland D.G., Radich J.P.;
RT   "Structural and numerical variation of FLT3/ITD in pediatric AML.";
RL   Blood 111:4930-4933(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18490735; DOI=10.4049/jimmunol.180.11.7358;
RA   Kikushige Y., Yoshimoto G., Miyamoto T., Iino T., Mori Y., Iwasaki H.,
RA   Niiro H., Takenaka K., Nagafuji K., Harada M., Ishikawa F., Akashi K.;
RT   "Human Flt3 is expressed at the hematopoietic stem cell and the
RT   granulocyte/macrophage progenitor stages to maintain cell survival.";
RL   J. Immunol. 180:7358-7367(2008).
RN   [18]
RP   PHOSPHORYLATION AT TYR-589; TYR-591; TYR-599; TYR-726; TYR-768;
RP   TYR-793; TYR-842 AND TYR-955.
RX   PubMed=19477218; DOI=10.1016/j.exphem.2009.05.008;
RA   Razumovskaya E., Masson K., Khan R., Bengtsson S., Ronnstrand L.;
RT   "Oncogenic Flt3 receptors display different specificity and kinetics
RT   of autophosphorylation.";
RL   Exp. Hematol. 37:979-989(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-759 AND SER-993, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN ACTIVATION OF FES AND FER, AND INTERACTION WITH FES AND
RP   FER.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=20508617; DOI=10.1038/leu.2010.114;
RA   Buchwald M., Pietschmann K., Muller J.P., Bohmer F.D., Heinzel T.,
RA   Kramer O.H.;
RT   "Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3
RT   for proteasomal degradation.";
RL   Leukemia 24:1412-1421(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=21067588; DOI=10.1186/1476-4598-9-292;
RA   Chen W., Drakos E., Grammatikakis I., Schlette E.J., Li J.,
RA   Leventaki V., Staikou-Drakopoulou E., Patsouris E., Panayiotidis P.,
RA   Medeiros L.J., Rassidakis G.Z.;
RT   "mTOR signaling is activated by FLT3 kinase and promotes survival of
RT   FLT3-mutated acute myeloid leukemia cells.";
RL   Mol. Cancer 9:292-292(2010).
RN   [23]
RP   INTERACTION WITH PTPRJ/DEP1, FUNCTION IN ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PLCG1; STAT5A AND/OR STAT5B, GLYCOSYLATION,
RP   UBIQUITINATION, AND PHOSPHORYLATION AT TYR-572; TYR-589; TYR-591;
RP   TYR-599; TYR-768; TYR-793; TYR-842 AND TYR-955.
RX   PubMed=21262971; DOI=10.1074/jbc.M110.205021;
RA   Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K.,
RA   Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D.,
RA   Muller J.P.;
RT   "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase
RT   FLT3 signaling.";
RL   J. Biol. Chem. 286:10918-10929(2011).
RN   [24]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=21516120; DOI=10.1038/onc.2011.110;
RA   Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M.,
RA   Small D.;
RT   "Further activation of FLT3 mutants by FLT3 ligand.";
RL   Oncogene 30:4004-4014(2011).
RN   [25]
RP   REVIEW.
RX   PubMed=12951584; DOI=10.1038/nrc1169;
RA   Stirewalt D.L., Radich J.P.;
RT   "The role of FLT3 in haematopoietic malignancies.";
RL   Nat. Rev. Cancer 3:650-665(2003).
RN   [26]
RP   REVIEW.
RX   PubMed=19549778; DOI=10.1158/1078-0432.CCR-08-1123;
RA   Meshinchi S., Appelbaum F.R.;
RT   "Structural and functional alterations of FLT3 in acute myeloid
RT   leukemia.";
RL   Clin. Cancer Res. 15:4263-4269(2009).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 564-958, AND ENZYME
RP   REGULATION.
RX   PubMed=14759363; DOI=10.1016/S1097-2765(03)00505-7;
RA   Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F.,
RA   Lippke J., Saxena K.;
RT   "The structural basis for autoinhibition of FLT3 by the juxtamembrane
RT   domain.";
RL   Mol. Cell 13:169-178(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 27-436 IN COMPLEX WITH
RP   FLT3LG, SUBUNIT, INTERACTION WITH FLT3LG, GLYCOSYLATION AT ASN-43;
RP   ASN-100; ASN-151; ASN-306; ASN-323; ASN-351 AND ASN-354,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND DISULFIDE BONDS.
RX   PubMed=21389326; DOI=10.1182/blood-2011-01-329532;
RA   Verstraete K., Vandriessche G., Januar M., Elegheert J.,
RA   Shkumatov A.V., Desfosses A., Van Craenenbroeck K., Svergun D.I.,
RA   Gutsche I., Vergauwen B., Savvides S.N.;
RT   "Structural insights into the extracellular assembly of the
RT   hematopoietic Flt3 signaling complex.";
RL   Blood 118:60-68(2011).
RN   [29]
RP   VARIANTS TYR-835 DEL; HIS-835 AND TYR-835, AND INVOLVEMENT IN AML.
RX   PubMed=11442493; DOI=10.1046/j.1365-2141.2001.02850.x;
RA   Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R.,
RA   Reilly J.T.;
RT   "Identification of novel FLT-3 Asp835 mutations in adult acute myeloid
RT   leukaemia.";
RL   Br. J. Haematol. 113:983-988(2001).
RN   [30]
RP   VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835,
RP   CHARACTERIZATION OF VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND
RP   TYR-835, PHOSPHORYLATION, AND INVOLVEMENT IN AML.
RX   PubMed=11290608; DOI=10.1182/blood.V97.8.2434;
RA   Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S.,
RA   Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K.,
RA   Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H.,
RA   Ueda R., Ohno R., Naoe T.;
RT   "Activating mutation of D835 within the activation loop of FLT3 in
RT   human hematologic malignancies.";
RL   Blood 97:2434-2439(2001).
RN   [31]
RP   VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836, FUNCTION
RP   IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION, AND
RP   INVOLVEMENT IN AML.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-158; MET-227; ASN-324; VAL-358 AND
RP   ILE-557.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-194.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for the cytokine FLT3LG and regulates differentiation,
CC       proliferation and survival of hematopoietic progenitor cells and
CC       of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and
CC       activation of the downstream effector MTOR. Promotes activation of
CC       RAS signaling and phosphorylation of downstream kinases, including
CC       MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES,
CC       FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B.
CC       Activation of wild-type FLT3 causes only marginal activation of
CC       STAT5A or STAT5B. Mutations that cause constitutive kinase
CC       activity promote cell proliferation and resistance to apoptosis
CC       via the activation of multiple signaling pathways.
CC       {ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:11090077,
CC       ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:18490735,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21067588,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21516120,
CC       ECO:0000269|PubMed:7507245}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15831474}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. FLT3LG binding leads to dimerization and
CC       activation by autophosphorylation. {ECO:0000269|PubMed:14759363,
CC       ECO:0000269|PubMed:21516120}.
CC   -!- SUBUNIT: Monomer in the absence of bound FLT3LG. Homodimer in the
CC       presence of bound FLT3LG. Interacts with FIZ1 following ligand
CC       activation (By similarity). Interacts with FES, FER, LYN, FGR,
CC       HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2.
CC       Interacts with RNF115 and RNF126 (By similarity).
CC       {ECO:0000250|UniProtKB:Q00342, ECO:0000269|PubMed:10080542,
CC       ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21389326,
CC       ECO:0000269|PubMed:9737679}.
CC   -!- INTERACTION:
CC       Q9Y6K9:IKBKG; NbExp=2; IntAct=EBI-3946257, EBI-81279;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-3946257, EBI-79464;
CC       Q12913:PTPRJ; NbExp=3; IntAct=EBI-3946257, EBI-2264500;
CC       P43405:SYK; NbExp=21; IntAct=EBI-3946257, EBI-78302;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum lumen. Note=Constitutively
CC       activated mutant forms with internal tandem duplications are less
CC       efficiently transported to the cell surface and a significant
CC       proportion is retained in an immature form in the endoplasmic
CC       reticulum lumen. The activated kinase is rapidly targeted for
CC       degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P36888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36888-2; Sequence=VSP_041796;
CC   -!- TISSUE SPECIFICITY: Detected in bone marrow, in hematopoietic stem
CC       cells, in myeloid progenitor cells and in granulocyte/macrophage
CC       progenitor cells (at protein level). Detected in bone marrow,
CC       liver, thymus, spleen and lymph node, and at low levels in kidney
CC       and pancreas. Highly expressed in T-cell leukemia.
CC       {ECO:0000269|PubMed:18490735, ECO:0000269|PubMed:7507245,
CC       ECO:0000269|PubMed:8394751, ECO:0000269|PubMed:8637232}.
CC   -!- DOMAIN: The juxtamembrane autoregulatory region is important for
CC       normal regulation of the kinase activity and for maintaining the
CC       kinase in an inactive state in the absence of bound ligand. Upon
CC       tyrosine phosphorylation, it mediates interaction with the SH2
CC       domains of numerous signaling partners. In-frame internal tandem
CC       duplications (ITDs) result in constitutive activation of the
CC       kinase. The activity of the mutant kinase can be stimulated
CC       further by FLT3LG binding.
CC   -!- PTM: N-glycosylated, contains complex N-glycans with sialic acid.
CC       {ECO:0000269|PubMed:15831474, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326}.
CC   -!- PTM: Autophosphorylated on several tyrosine residues in response
CC       to FLT3LG binding. FLT3LG binding also increases phosphorylation
CC       of mutant kinases that are constitutively activated.
CC       Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a
CC       lesser degree by PTPN12. Dephosphorylation is important for export
CC       from the endoplasmic reticulum and location at the cell membrane.
CC   -!- PTM: Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein
CC       ligase SIAH1 after autophosphorylation, leading to its proteasomal
CC       degradation. {ECO:0000269|PubMed:20508617,
CC       ECO:0000269|PubMed:21262971}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:11290608,
CC       ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:18305215,
CC       ECO:0000269|PubMed:8946930, ECO:0000269|PubMed:9737679}. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis. Somatic mutations that lead to constitutive
CC       activation of FLT3 are frequent in AML patients. These mutations
CC       fall into two classes, the most common being in-frame internal
CC       tandem duplications of variable length in the juxtamembrane region
CC       that disrupt the normal regulation of the kinase activity.
CC       Likewise, point mutations in the activation loop of the kinase
CC       domain can result in a constitutively activated kinase.
CC   -!- MISCELLANEOUS: Can be used as diagnostic tool to establish the
CC       exact cause of acute myeloid leukemia, and to determine the
CC       optimal therapy.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FLT3ID144.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U02687; AAA18947.1; -; mRNA.
DR   EMBL; Z26652; CAA81393.1; -; mRNA.
DR   EMBL; AL356915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08424.1; -; Genomic_DNA.
DR   EMBL; BC126350; AAI26351.1; -; mRNA.
DR   EMBL; BC144039; AAI44040.1; -; mRNA.
DR   EMBL; BC144040; AAI44041.1; -; mRNA.
DR   EMBL; L36162; AAA35487.1; -; mRNA.
DR   CCDS; CCDS31953.1; -. [P36888-1]
DR   PIR; A36873; A36873.
DR   PIR; A39061; A39061.
DR   RefSeq; NP_004110.2; NM_004119.2. [P36888-1]
DR   UniGene; Hs.507590; -.
DR   PDB; 1RJB; X-ray; 2.10 A; A=564-907.
DR   PDB; 3QS7; X-ray; 4.30 A; E/F/G/H=27-436.
DR   PDB; 3QS9; X-ray; 7.80 A; E/F/G/H=27-540.
DR   PDB; 4RT7; X-ray; 3.10 A; A=564-958.
DR   PDB; 4XUF; X-ray; 3.20 A; A/B=600-947.
DR   PDBsum; 1RJB; -.
DR   PDBsum; 3QS7; -.
DR   PDBsum; 3QS9; -.
DR   PDBsum; 4RT7; -.
DR   PDBsum; 4XUF; -.
DR   ProteinModelPortal; P36888; -.
DR   SMR; P36888; -.
DR   BioGrid; 108610; 11.
DR   DIP; DIP-59769N; -.
DR   IntAct; P36888; 5.
DR   MINT; MINT-7103562; -.
DR   STRING; 9606.ENSP00000241453; -.
DR   BindingDB; P36888; -.
DR   ChEMBL; CHEMBL1974; -.
DR   DrugBank; DB06080; ABT-869.
DR   DrugBank; DB05213; AC220.
DR   DrugBank; DB05465; MLN-518.
DR   DrugBank; DB05216; MP470.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05014; XL999.
DR   GuidetoPHARMACOLOGY; 1807; -.
DR   iPTMnet; P36888; -.
DR   PhosphoSitePlus; P36888; -.
DR   BioMuta; FLT3; -.
DR   DMDM; 156630887; -.
DR   MaxQB; P36888; -.
DR   PaxDb; P36888; -.
DR   PeptideAtlas; P36888; -.
DR   PRIDE; P36888; -.
DR   Ensembl; ENST00000241453; ENSP00000241453; ENSG00000122025. [P36888-1]
DR   GeneID; 2322; -.
DR   KEGG; hsa:2322; -.
DR   UCSC; uc001urw.3; human. [P36888-1]
DR   CTD; 2322; -.
DR   DisGeNET; 2322; -.
DR   GeneCards; FLT3; -.
DR   H-InvDB; HIX0037338; -.
DR   HGNC; HGNC:3765; FLT3.
DR   HPA; HPA047539; -.
DR   MalaCards; FLT3; -.
DR   MIM; 136351; gene.
DR   MIM; 601626; phenotype.
DR   neXtProt; NX_P36888; -.
DR   OpenTargets; ENSG00000122025; -.
DR   Orphanet; 98829; 'Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)'.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   Orphanet; 98837; Acute biphenotypic leukemia.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 98832; Minimally differentiated acute myeloblastic leukemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28181; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOVERGEN; HBG005735; -.
DR   InParanoid; P36888; -.
DR   KO; K05092; -.
DR   OMA; GPIYLIF; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P36888; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-449147; Signaling by Interleukins.
DR   SignaLink; P36888; -.
DR   SIGNOR; P36888; -.
DR   EvolutionaryTrace; P36888; -.
DR   GeneWiki; CD135; -.
DR   GenomeRNAi; 2322; -.
DR   PRO; PR:P36888; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000122025; -.
DR   CleanEx; HS_FLT3; -.
DR   ExpressionAtlas; P36888; baseline and differential.
DR   Genevisible; P36888; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004896; F:cytokine receptor activity; ISS:UniProtKB.
DR   GO; GO:0035259; F:glucocorticoid receptor binding; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IMP:CAFA.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0035726; P:common myeloid progenitor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0001776; P:leukocyte homeostasis; ISS:UniProtKB.
DR   GO; GO:0046651; P:lymphocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; TAS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:UniProtKB.
DR   GO; GO:0002328; P:pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR030118; FLT3.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF395; PTHR24416:SF395; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27    993       Receptor-type tyrosine-protein kinase
FT                                FLT3.
FT                                /FTId=PRO_0000016778.
FT   TOPO_DOM     27    543       Extracellular. {ECO:0000255}.
FT   TRANSMEM    544    563       Helical. {ECO:0000255}.
FT   TOPO_DOM    564    993       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      253    343       Ig-like C2-type.
FT   DOMAIN      610    943       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     616    624       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      591    597       Important for normal regulation of the
FT                                kinase activity and for maintaining the
FT                                kinase in an inactive state in the
FT                                absence of bound ligand.
FT   ACT_SITE    811    811       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     644    644       ATP. {ECO:0000305}.
FT   MOD_RES     572    572       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     574    574       Phosphoserine.
FT                                {ECO:0000269|PubMed:16684964}.
FT   MOD_RES     589    589       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     591    591       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15831474,
FT                                ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     599    599       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     726    726       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218}.
FT   MOD_RES     759    759       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     768    768       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     793    793       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     842    842       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     955    955       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     969    969       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759}.
FT   MOD_RES     993    993       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    151    151       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    473    473       N-linked (GlcNAc...) asparagine.
FT   CARBOHYD    502    502       N-linked (GlcNAc...) asparagine.
FT   CARBOHYD    541    541       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     35     65       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    103    114       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    199    206       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    232    241       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    272    330       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    368    407       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    381    392       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   VAR_SEQ     807    847       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041796.
FT   VARIANT       7      7       D -> G (in dbSNP:rs12872889).
FT                                /FTId=VAR_034677.
FT   VARIANT     158    158       V -> A (in dbSNP:rs56321896).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042069.
FT   VARIANT     194    194       V -> M (in dbSNP:rs146030737).
FT                                {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054149.
FT   VARIANT     227    227       T -> M (in dbSNP:rs1933437).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8394751,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034678.
FT   VARIANT     324    324       D -> N (in dbSNP:rs35602083).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042070.
FT   VARIANT     358    358       D -> V (in dbSNP:rs34172843).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042071.
FT   VARIANT     417    417       I -> L (in dbSNP:rs56090538).
FT                                /FTId=VAR_061291.
FT   VARIANT     557    557       V -> I (in dbSNP:rs35958982).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042072.
FT   VARIANT     835    835       D -> E (in acute lymphoblastic leukemia
FT                                patients and acute myelogenous leukemia
FT                                patients; somatic mutation;
FT                                constitutively activated;
FT                                dbSNP:rs121913487).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065679.
FT   VARIANT     835    835       D -> H (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated;
FT                                dbSNP:rs121913488).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:11442493,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065680.
FT   VARIANT     835    835       D -> N (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated;
FT                                dbSNP:rs121913488).
FT                                {ECO:0000269|PubMed:11290608}.
FT                                /FTId=VAR_065681.
FT   VARIANT     835    835       D -> V (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated;
FT                                dbSNP:rs121909646).
FT                                {ECO:0000269|PubMed:11290608}.
FT                                /FTId=VAR_065682.
FT   VARIANT     835    835       D -> Y (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated;
FT                                dbSNP:rs121913488).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:11442493,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065683.
FT   VARIANT     836    836       I -> M (in acute lymphoblastic leukemia
FT                                patients; somatic mutation;
FT                                dbSNP:rs121913232).
FT                                {ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065684.
FT   MUTAGEN     589    589       Y->F: Reduced phosphorylation of the
FT                                wild-type kinase in response to ligand
FT                                binding. No effect on the phosphorylation
FT                                of the constitutively activated mutant
FT                                kinase variants. Abolishes activation of
FT                                STAT5A. {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:9737679}.
FT   MUTAGEN     591    591       Y->F: No significant effect on tyrosine
FT                                phosphorylation. Abolishes activation of
FT                                STAT5A. {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:9737679}.
FT   MUTAGEN     599    599       Y->F: Abolishes interaction with
FT                                PTPN11/SHP2 and phosphorylation of
FT                                PTPN11/SHP2.
FT                                {ECO:0000269|PubMed:16684964}.
FT   MUTAGEN     644    644       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15831474}.
FT   CONFLICT      8      8       G -> A (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT     10     11       QL -> TV (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT     71     71       S -> N (in Ref. 5; AAI44040).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       A -> R (in Ref. 2; CAA81393).
FT                                {ECO:0000305}.
FT   CONFLICT    346    346       E -> G (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT    940    940       T -> H (in Ref. 6; AAA35487).
FT                                {ECO:0000305}.
FT   STRAND      575    581       {ECO:0000244|PDB:1RJB}.
FT   STRAND      583    585       {ECO:0000244|PDB:1RJB}.
FT   STRAND      589    591       {ECO:0000244|PDB:1RJB}.
FT   HELIX       594    596       {ECO:0000244|PDB:1RJB}.
FT   HELIX       601    603       {ECO:0000244|PDB:1RJB}.
FT   HELIX       607    609       {ECO:0000244|PDB:1RJB}.
FT   STRAND      610    618       {ECO:0000244|PDB:1RJB}.
FT   STRAND      620    631       {ECO:0000244|PDB:1RJB}.
FT   STRAND      633    636       {ECO:0000244|PDB:1RJB}.
FT   STRAND      638    646       {ECO:0000244|PDB:1RJB}.
FT   HELIX       656    668       {ECO:0000244|PDB:1RJB}.
FT   STRAND      677    681       {ECO:0000244|PDB:1RJB}.
FT   STRAND      683    686       {ECO:0000244|PDB:1RJB}.
FT   STRAND      688    692       {ECO:0000244|PDB:1RJB}.
FT   HELIX       699    704       {ECO:0000244|PDB:1RJB}.
FT   TURN        705    708       {ECO:0000244|PDB:1RJB}.
FT   HELIX       785    804       {ECO:0000244|PDB:1RJB}.
FT   STRAND      807    809       {ECO:0000244|PDB:1RJB}.
FT   HELIX       814    816       {ECO:0000244|PDB:1RJB}.
FT   STRAND      817    820       {ECO:0000244|PDB:1RJB}.
FT   TURN        821    823       {ECO:0000244|PDB:1RJB}.
FT   STRAND      824    827       {ECO:0000244|PDB:1RJB}.
FT   HELIX       831    833       {ECO:0000244|PDB:1RJB}.
FT   HELIX       836    838       {ECO:0000244|PDB:1RJB}.
FT   STRAND      842    845       {ECO:0000244|PDB:1RJB}.
FT   STRAND      848    850       {ECO:0000244|PDB:1RJB}.
FT   HELIX       852    854       {ECO:0000244|PDB:1RJB}.
FT   HELIX       857    862       {ECO:0000244|PDB:1RJB}.
FT   HELIX       867    881       {ECO:0000244|PDB:1RJB}.
FT   TURN        882    884       {ECO:0000244|PDB:1RJB}.
FT   HELIX       896    903       {ECO:0000244|PDB:1RJB}.
FT   HELIX       916    924       {ECO:0000244|PDB:4RT7}.
FT   HELIX       930    932       {ECO:0000244|PDB:4RT7}.
FT   HELIX       936    949       {ECO:0000244|PDB:4RT7}.
SQ   SEQUENCE   993 AA;  112903 MW;  6C1995718F352ECE CRC64;
     MPALARDGGQ LPLLVVFSAM IFGTITNQDL PVIKCVLINH KNNDSSVGKS SSYPMVSESP
     EDLGCALRPQ SSGTVYEAAA VEVDVSASIT LQVLVDAPGN ISCLWVFKHS SLNCQPHFDL
     QNRGVVSMVI LKMTETQAGE YLLFIQSEAT NYTILFTVSI RNTLLYTLRR PYFRKMENQD
     ALVCISESVP EPIVEWVLCD SQGESCKEES PAVVKKEEKV LHELFGTDIR CCARNELGRE
     CTRLFTIDLN QTPQTTLPQL FLKVGEPLWI RCKAVHVNHG FGLTWELENK ALEEGNYFEM
     STYSTNRTMI RILFAFVSSV ARNDTGYYTC SSSKHPSQSA LVTIVEKGFI NATNSSEDYE
     IDQYEEFCFS VRFKAYPQIR CTWTFSRKSF PCEQKGLDNG YSISKFCNHK HQPGEYIFHA
     ENDDAQFTKM FTLNIRRKPQ VLAEASASQA SCFSDGYPLP SWTWKKCSDK SPNCTEEITE
     GVWNRKANRK VFGQWVSSST LNMSEAIKGF LVKCCAYNSL GTSCETILLN SPGPFPFIQD
     NISFYATIGV CLLFIVVLTL LICHKYKKQF RYESQLQMVQ VTGSSDNEYF YVDFREYEYD
     LKWEFPRENL EFGKVLGSGA FGKVMNATAY GISKTGVSIQ VAVKMLKEKA DSSEREALMS
     ELKMMTQLGS HENIVNLLGA CTLSGPIYLI FEYCCYGDLL NYLRSKREKF HRTWTEIFKE
     HNFSFYPTFQ SHPNSSMPGS REVQIHPDSD QISGLHGNSF HSEDEIEYEN QKRLEEEEDL
     NVLTFEDLLC FAYQVAKGME FLEFKSCVHR DLAARNVLVT HGKVVKICDF GLARDIMSDS
     NYVVRGNARL PVKWMAPESL FEGIYTIKSD VWSYGILLWE IFSLGVNPYP GIPVDANFYK
     LIQNGFKMDQ PFYATEEIYI IMQSCWAFDS RKRPSFPNLT SFLGCQLADA EEAMYQNVDG
     RVSECPHTYQ NRRPFSREMD LGLLSPQAQV EDS
//
